Covid Antibody Test Kits

625.00 inc. VAT @23%

SOLD in Boxes of 25 tests

German manufactured MEXACARE COVID-19 IgG/IgM Antibody Test is a rapid, qualitative immunochromatographic assay for the differential detection of IgM & IgG antibodies against SARS CoV-2 virus in human serum, plasma or whole blood samples. The test is intended for the determination of a current or past infection with the SARS-CoV-2 virus and for monitoring the disease status after SARS-CoV-2 virus infection.

The MEXACARE COVID-19 IgG/IgM Rapid Test has a sensitivity of 94.55% and a specificity of 97.26%.

MEXACARE GmbH is an ISO 13485 certified manufacturer for rapid medical tests.

The advantages of Mexacare COVID-19 IgG/IgM Rapid Test:

  • European CE Certified. In vitro diagnostic medical devices compliant
  • 97.26% Accuracy
  • Regulatory approved European manufacturers collaborating with Abbott, Siemens and Roche
  • Test device for qualitative and selective detection
  • Fast, easy, inexpensive – No lab equipment needed
  • Safe point of care test with result within 15-20 minutes √ High Specificity (>97%) allows fast detection of infected people
  • Detection of antibodies even in patients without symptoms
  • Complements RT-PCR as a powerful tool to broadly assess spread of virus
  • Proven reliability through comprehensive clinical study (more than 700 test subjects)
  • Important diagnostic gap for the detection of an earlier immune reaction is closed
  • Proof of immunity of patients, and to lift quarantine measures
  • Offers the possibility of effective screening of large parts of the population
  • Compared to competitive products, the MEXACARE COVID-19 IgG/IgM Antibody Test has clearer bands, which makes it easier to read


Download Mexacare rapid test  Data Sheet


SOLD in Boxes of 25 tests


SKU: 007-1 Categories: ,
Additional Information
Weight0.01 kg
Why are antibody tests useful?

Antibody tests can fill a diagnostic gap. In the earlier phases of the disease – several days after
the onset of symptoms – the IgM antibody test can be used to screen for active infections with
SARS-CoV-2 and help to distinguish between COVID-19 and other respiratory diseases such

as influenza or RSV. In the later stages, the IgG antibody test can help to detect previously un-
detected infections and screen the serological immunity of large numbers of the population. In

addition, the IgG antibodies remain in the body for a long time after the patient has recovered.
Therefore, the result is a marker for successful convalescence in ONLY IgG-positive patients.
Since antibody tests are much faster and easier to perform, the extended use of these tests
could relieve the laboratories and help to keep capacity at the same level.

When should I test with the COVID-19 IgG/IgM Rapid Test?

The COVID-19 IgG/IgM Rapid Test is intended to complement the RT-PCR tests, which are cur-
rently performed in large numbers by doctors, laboratories and public health authorities throug-
hout the world in the fight against the novel Corona-Virus SARS-CoV-2.

During the earliest stages of the disease – in the incubation period (according to WHO around 5-6
days on average) and on the first 2-3 days after the onset of symptoms – only RT-PCR can give
you satisfactory test results as the body has not produced antibodies in detectable quantities.
5-7 days after the onset of the disease symptoms (cough, slight fever, sore throat) IgM antibodies
can already be detected in the blood. After this period of approx. 7 days, we recommend testing

with the COVID-19 IgG/IgM rapid test, as positive results can now be obtained with a high de-
gree of certainty. IgG antibodies are later produced by the immune system and can be detected

in the body long after recovery. In this way, undetected infections (e.g. infections without symp-
toms) or the serological protection of the test subject can be determined.